NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum Flavored) 16 fl. oz. (480 mL) Manufactured by: VistaPharm, Inc. Largo FL 33771, USA NDC 66689-008-16 UPC 6668900816,

Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot

Recall #: D-0019-2021
Affected scope: 14,244 16 oz bottles
Initiated: September 25, 2020

Compiled from official public sources by the publisher. · Updated September 2026

VistaPharm, Inc. recalled NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum … - a low-severity action.

NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum … was recalled by VistaPharm, Inc. in October 14, 2020. Reason: Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot. Check the official notice for the remedy. Verify recall #D-0019-2021 with the FDA Drug before acting.

The recall

VistaPharm, Inc. issued this low-severity FDA Drug recall-Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot.

Low
severity level: Class III
classification: October 14, 2020
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0019-2021 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

NYSTATIN ORAL SUSPENSION, USP 100,000 units per mL Contains: Alcohol 0.5% v/v (Bubblegum Flavored) 16 fl. oz. (480 mL) Manufactured by: VistaPharm, Inc. Largo FL 33771, USA NDC 66689-008-16 UPC 6668900816,

Reason for recall

Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-0019-2021
Date reported	October 14, 2020
Date initiated	September 25, 2020
Recalling firm	VistaPharm, Inc.
Firm location	Largo, FL
Affected scope	14,244 16 oz bottles
Distribution	Distributed Nationwide in the USA including Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-0019-2021) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on October 14, 2020. Severity: Low. Recall number: D-0019-2021.

Where was the recalled product distributed? ▼

Distribution: Distributed Nationwide in the USA including Puerto Rico.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Citalopram Oral Solution, USP 20 mg/10 mL… 2020-10-14 Neoprobe GDS Control Unit, Model Number N… 2020-10-14 Cystaran (cysteamine ophthalmic solution)… 2020-10-21 Tina-quant Complement C4 ver.2, Catalog 0… 2020-10-21

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Nature-Throid 1 GR (65 mg), Each Tablet C… 2020-10-14 Diethylpropion, 25 mg tablets, Rx only, D… 2020-10-14 Diethylpropion, 75 mg tablets, Rx only, D… 2020-10-14 Phentermine, 30 mg capsules, Rx only, Dis… 2020-10-14

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported October 14, 2020. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026